An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) — Stella
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(18 sites)
United States
Clinical Site, North Little Rock, Arkansas
Clinical Site, Stanford, California
Clinical Site, Washington D.C., District of Columbia